Please login to the form below

Not currently logged in
Email:
Password:

Keytruda

This page shows the latest Keytruda news and features for those working in and with pharma, biotech and healthcare.

Keytruda now available for untreated metastatic lung cancer patients via Cancer Drugs Fund

Keytruda now available for untreated metastatic lung cancer patients via Cancer Drugs Fund

MSD will also be required to provide Keytruda according to the managed access agreement it already has in place with NICE. ... NICE has however maintained that the clinical evidence is immature and maintains that the cost-effectiveness of Keytruda

Latest news

More from news
Approximately 126 fully matching, plus 204 partially matching documents found.

Latest Intelligence

  • 25 Women Leaders in UK Healthcare 25 Women Leaders in UK Healthcare

    its role in developing immuno-oncology blockbuster Keytruda. ... The coming Keytruda windfall will also allow the charity to set up a stand-alone venture capital division, with which it could seed funding and help promote research in key areas.

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), and the

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast. ... On 28 December, Keytruda gained FDA clearance for use in Merkel cell carcinoma.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1 inhibitor Keytruda (pembrolizumab) was backed for cancers harbouring a biomarker known as microsatellite instability-high (MSI-H). ... Merck/MSD looks to have gained a dominant position in checkpoint inhibitor immuno-oncology (IO) with Keytruda – but

  • The UK’s new five-year pricing agreement The UK’s new five-year pricing agreement

    of this include recent deals on CAR-T therapies, plus a new expansion in the use of Keytruda in lung cancer, announced late last year.

More from intelligence
Approximately 0 fully matching, plus 17 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics